Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma

✍ Scribed by Marc C. Chamberlain

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 299 KB
• Volume: 73
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19940315)73:6<1728::aid-cncr2820730629>3.0.co;2-8

✦ Synopsis

Background. Primary central nervous system lymphoma (PCNSL) is the most common brain tumor occurring in patients with acquired immune deficiency syndrome (AIDS). After diagnosis of PCNSL, the median sur- vival time is 2-5 months with treatment with whole brain irradiation (WBI).

Methods. Four (of approximately 40) patients with AIDS and PCNSL seen by the University of California, San Diego (UCSD) Neuro-Oncology service were treated with multimodal therapy, including WBI with hydroxyurea, followed by 3 cycles of procarbazine/lomustine/ vincristine (PCV) chemotherapy.

Results. Survival after tumor diagnosis ranged from 11 to 16 months, with a median of 13.5 months.

Conclusion.

Selected patients with AIDS and PCNSL may have long survival when treated with multimodal therapy. Cancer 1994; 739728-30.